06833 SINCO PHARMA
- 0.250
- -0.005-1.96%
SINCO PHARMA News
興科蓉醫藥：年報 2023
Xingkerong Pharmaceutical (6833.HK): Revenue increased 11.8% year over year, ready to go
In 2023, in an environment where external uncertainties still exist, the Hong Kong stock pharmaceutical market experienced significant fluctuations, and the sector is still below the historical valuation center. However, there are still excellent companies in the pharmaceutical sector that have shown good ability to cross the cycle, and have performed well with high performance flexibility and stable fundamentals, such as Xingkerong Pharmaceutical, a leading marketing, promotion and channel management service provider in the domestic pharmaceutical industry. Recently, Xingkerong Pharmaceutical announced its 2023 annual results. According to the results announcement, the company's revenue achieved a steady increase of 11.8%, reaching RMB 2.54 billion. This one percent
Sinco Pharmaceuticals' 2023 Profit Declines on Higher Tax Payments
Sinco Pharmaceuticals Holdings' (HKG:6833) attributable profit declined to 42.4 million yuan, or 0.021 yuan per share, in 2023, from 69.5 million yuan, or 0.034 yuan per share, in 2022, according to a
Xingkerong Pharmaceutical (06833) Announces 2023 Annual Results, Excellent Core Product Results, Dual Track Layout Continues to Deepen and Advance
The Zhitong Finance App learned that on the evening of March 26, Xingkerong Pharmaceutical (06833) announced its 2023 annual results, with revenue growth of 11.8% to RMB 2,540.1 million. Among them, sales revenue of human albumin injections increased by about RMB 249.8 million, and revenue from the medical and aesthetic business increased by RMB 13.7 million. During the reporting period, the company's gross profit increased by RMB 17.4 million to RMB 323.3 million. The increase in gross profit was mainly due to increased revenue from human albumin sales and medical and aesthetic services. At the same time, in order to return long-term shareholders' support, the company's board of directors recommended declaring a final dividend per share
Xingkerong Pharmaceutical (06833.HK) revenue increased 11.8% to 2.54 billion yuan in 2023
Gelonghui, March 26, 丨 Xingkerong Pharmaceutical (06833.HK) announced that in its annual results for the year ended December 31, 2023, the Group's revenue increased 11.8% to RMB 2.54 billion. Among them, sales revenue of human albumin injections increased by about RMB 250 million, mainly due to the increase in sales volume. During the reporting period, net profit attributable to company owners was RMB 42.4 million; basic and apportioned profit per share was RMB 0.02 (2022: basic and diluted earnings per share of RMB 0.03). Board resolution for the year ended 31 December 2023
Xingkerong Pharmaceutical (06833) announced annual results. Profit attributable to shareholders of RMB 42.352 million decreased by 39.03% year-on-year, with final interest of HK0.39 cents per share
Xingkerong Pharmaceutical (06833) announced the results for the year ended December 31, 2023. The group's beneficiaries...
Xingkerong Pharmaceutical (06833) will pay a final dividend of HK$0.0039 per share on June 4
Xingkerong Pharmaceutical (06833) announced that the company will distribute the end of 2023 on June 4, 2024...
SINCO PHARMA: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Xing Kerong Pharmaceutical (06833): Huang Zhijian was appointed as Executive Director
Xingkerong Pharmaceutical (06833) announced that Li Jianwei has resigned as the company's joint company secretary and the Hong Kong Stock Exchange Limited...
Xingkerong Pharmaceutical (06833.HK) held a board meeting on March 26 to consider and approve annual results
Gelonghui, March 14, 丨 Xingkerong Pharmaceutical (06833.HK) announced that the company will hold a board meeting on March 26, 2024 (Tuesday) to consider and approve the results and publication of the company and its subsidiaries for the year ended 31 December 2023, and to consider recommending payment of a final dividend (if any).
SINCO PHARMA: DATE OF BOARD MEETING
Sinco Pharmaceuticals Warns of Lower 2023 Profit
Sinco Pharmaceuticals Holdings (HKG:6833) expects an attributable net profit of around 42 million yuan for the year ended December 2023, as against a net profit of 69.5 million yuan in 2022, according
Xingkerong Pharmaceutical (06833) Fa Ying Guang expects net profit attributable to shareholders of about 42 million yuan in 2023 to decrease by about 39.6% year-on-year
Xingkerong Pharmaceutical (06833) issued an announcement. The Group expects the year ended December 31, 2023 (this year...
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Pioneer Securities Pharmaceutical's 24-year Strategy: Risks have been fully released, and subsequent industry valuations are expected to rise steadily
The Zhitong Finance App learned that Pioneer Securities released a research report saying that due to more scientific collection rules, after the collection gradually covered a large stock of generic drugs/high-value consumables, the performance was clear, and new performance growth points were formed after innovative products were launched one after another, and the drugs/device-related companies in the hospital will usher in a new growth cycle after their performance stabilizes.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
CITIC Construction Investment: The innovative drug sector has reached the bottom of the valuation to seize multi-line opportunities and focus on systematized pharmaceutical companies entering the harvest period
CITIC Construction Investment released a research report saying that the innovative pharmaceutical industry is expected to achieve good growth in 2024, and is optimistic about the sector's performance.
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
Guotai Junan: The pharmaceutical sector valuation system has entered a small cycle of grasping business operations during a relatively stable period
The Zhitong Finance App learned that Guotai Junan released a research report saying that in 2019-2023, the collection, epidemic, etc. affected industries. It is anticipated that 2024, regardless of whether it has had the greatest positive or negative impact, has passed, returning to the main logic driven by healthcare demand.
Analysis
Price Target
No Data
